Table 3.
Matrix of pairwise comparison among hypoglycemic drugs on ADAS-Cog score (shown as mean difference and 95% confidence intervals).
| MTN | Placebo | RLZ2 | PLZ | RLZ10 | GLP-1 | ITSN40 | RLZ4 | RLZ8 | ITSN20 | |
|---|---|---|---|---|---|---|---|---|---|---|
| SUCRA (%) | 86.6 | 82.4 | 79.6 | 61.6 | 52.2 | 47.6 | 34.8 | 31.8 | 12.9 | 10.5 |
| MTN | 0 | −0.20 (−1.11, 0.72) | −0.19 (−1.41, 1.04) | −0.55 (−1.74, 0.64) | −0.75 (−2.00, 0.49) | −0.82 (−2.17, 0.53) | −1.08 (−2.22, 0.06) | −1.12 (−2.37, 0.12) | −1.59 (−2.84, −0.34) | −0.03 (-1.42,1.35) |
| Placebo | 0.20 (−0.72, 1.11) | 0 | 0.36 (−0.81, 1.53) | −0.35 (−1.11, 0.40) | −3.02 (−4.17, −1.86) | −0.62 (−1.62, 0.37) | −1.88 (−3.09, −0.66) | −1.40 (−2.57, −0.23) | 0.01 (−0.80, 0.82) | −0.92 (-1.77,-0.08) |
| RLZ2 | 0.19 (−1.04, 1.41) | −0.36 (−1.53, 0.81) | 0 | −0.37 (−1.47, 0.74) | −0.57 (−1.74, 0.60) | −0.63 (−1.92, 0.65) | −0.90 (−1.95, 0.16) | −0.94 (−2.11, 0.23) | −1.40 (−2.57, −0.23) | 0.15 (-1.17,1.47) |
| PLZ | 0.55 (−0.64, 1.74) | 0.35 (−0.40, 1.11) | 0.37 (−0.74, 1.47) | 0 | −0.20 (−1.33, 0.93) | −0.27 (−1.52, 0.98) | −0.53 (−1.55, 0.48) | −0.57 (−1.70, 0.56) | −1.04 (−2.17, 0.10) | 0.52 (-0.77,1.80) |
| RLZ10 | 0.75 (−0.49, 2.00) | 3.02 (1.86, 4.17) | 0.57 (−0.60, 1.74) | 0.20 (−0.93, 1.33) | 0 | −0.07 (−1.37, 1.24) | −0.33 (−1.41, 0.75) | −0.37 (−1.21, 0.47) | −0.83 (−2.03, 0.36) | 0.72 (-0.62,2.06) |
| GLP-1 | 0.82 (−0.53, 2.17) | 0.62 (−0.37, 1.62) | 0.63 (−0.65, 1.92) | 0.27 (−0.98, 1.52) | 0.07 (−1.24, 1.37) | 0 | −0.26 (−1.47, 0.94) | −0.30 (−1.61, 1.00) | −0.77 (−2.07, 0.54) | 0.78 (-0.66,2.23) |
| ITSN40 | 1.08 (−0.06, 2.22) | 1.88 (0.66, 3.09) | 0.90 (−0.16, 1.95) | 0.53 (−0.48, 1.55) | 0.33 (−0.75, 1.41) | 0.26 (−0.94, 1.47) | 0 | −0.04 (−1.12, 1.04) | −0.50 (−1.59, 0.58) | 1.05 (-0.20,2.29) |
| RLZ4 | 1.12 (−0.12, 2.37) | 1.40 (0.23, 2.57) | 0.94 (−0.23, 2.11) | 0.57 (−0.56, 1.70) | 0.37 (−0.47, 1.21) | 0.30 (−1.00, 1.61) | 0.04 (−1.04, 1.12) | 0 | −0.47 (−1.66, 0.73) | 1.09 (-0.25,2.43) |
| RLZ8 | 1.59 (0.34, 2.84) | −0.01 (−0.82, 0.80) | 1.40 (0.23, 2.57) | 1.04 (−0.10, 2.17) | 0.83 (−0.36, 2.03) | 0.77 (−0.54, 2.07) | 0.50 (−0.58, 1.59) | 0.47 (−0.73, 1.66) | 0 | 1.55 (0.21,2.90) |
| ITSN20 | 0.03 (−1.35, 1.42) | 0.92 (0.08, 1.77) | −0.15 (−1.47, 1.17) | −0.52 (−1.80, 0.77) | −0.72 (−2.06, 0.62) | −0.78 (−2.23, 0.66) | −1.05 (−2.29, 0.20) | −1.09 (−2.43, 0.25) | −1.55 (−2.90, −0.21) | 0 |
SUCRA, Surface under the cumulative ranking curve; ITSN20, Intranasal insulin 20IU; ITSN40, Intranasal insulin 40IU; MTN, Metformin; PLZ, Pioglitazone; RLZ2, Rosiglitazone 2 mg; RLZ4, Rosiglitazone 4 mg; RLZ8, Rosiglitazone 8 mg; RLZ10, Rosiglitazone 10 mg; GLP-1, Glucagon-like Peptide-1; ADAS-Cog score, Alzheimer's Disease Assessment Scale-Cognitive section.